PTGS2 and inflammatory bowel disease: In inflammatory bowel disease (IBD), PUFAs of the n-3 series have reported to exert an inhibitory action on PTGS2 gene expression in vivo using a genetically-modified mouse 106; they compete with arachidonic acid (AA) for binding to the COX-2 catalytic site and finally obstructed prostaglandin formation 107.